Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.65 |
| ▸ | SLC6A2 known ✓ | P23975 | 11/20 | 0.65 |
| ▸ | HTR1B known ✓ | P28222 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9995405 | 0.99 | SLC6A4 (0.67) | SLC6A4SLC6A2HTR1BHRH3CACNA2D1 | |
| Maleic Acid SCHEMBL7311827 | 0.89 | SLC6A2 (0.56) | SLC6A4SLC6A2HTR1BUTS2R | |
| SCHEMBL25670014 | 0.86 | SLC6A4 (0.62) | SLC6A4SLC6A2HTR1B | |
| SCHEMBL5080333 | 0.85 | CACNA2D1 (0.57) | SLC6A4SLC6A2HTR1BCACNA2D1 | |
| Iodide SCHEMBL2607 | 0.84 | CACNA2D1 (0.56) | SLC6A4SLC6A2HTR1BCACNA2D1 | |
| SCHEMBL3458 | 0.83 | SLC6A2 (0.71) | SLC6A4SLC6A2HTR1BCACNA2D1 | |
| Oxalic Acid SCHEMBL3521 | 0.82 | CACNA2D1 (0.52) | SLC6A4SLC6A2HTR1BCACNA2D1UTS2R | |
| SCHEMBL8026016 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A2HRH3UTS2R | |
| Bromide SCHEMBL6903611 | 0.81 | SLC6A2 (0.66) | SLC6A4SLC6A2HTR1B | |
| SCHEMBL8285421 | 0.81 | SLC6A4 (0.69) | SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-12-30 | — | — | US | claimed |
| EP-1425002-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENTS IN THE TREATMENT OF CANCER | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-09 | — | — | EP | claimed |
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2004-03-18 | — | — | US | claimed |
| US-6630454-B2 | Method and pharmaceutical composition for the treatment of cancer | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2003-10-07 | — | — | US | claimed |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. | 2003-05-08 | — | — | US | claimed |
| WO-2003022258-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-03-20 | — | — | WO | claimed |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| EP-1425002-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENTS IN THE TREATMENT OF CANCER | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-09 | — | — | EP | disclosed |
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6630454-B2 | Method and pharmaceutical composition for the treatment of cancer | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2003-10-07 | — | — | US | disclosed |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. | 2003-05-08 | — | — | US | disclosed |
| WO-2003022258-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | ABCC1, ABCB1, SLC11A2 | SLC6A4 340/4885SLC6A2 374/4885HTR1B 597/4885 |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | PNMT, ABCC1, HNMT | SLC6A4 596/4885SLC6A2 550/4885HTR1B 457/4885 |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | ABCC1, PNMT, ABCB1 | SLC6A4 280/4885SLC6A2 290/4885HTR1B 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.